ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Abbas E. Abbas
Larry R. Kaiser
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lambright, E. S.
Right arrow Articles by Kaiser, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambright, E. S.
Right arrow Articles by Kaiser, L. R.

Ann Thorac Surg 1999;68:1756-1760
© 1999 The Society of Thoracic Surgeons

Original Articles

Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system

Eric S. Lambright, MDa, David J. Caparrelli, MDa, Abbas E. Abbas, MDa, Takane Toyoizumi, MDa, George Coukos, MDa, Katherine L. Molnar-Kimber, PhDa, Larry R. Kaiser, MDa

a Thoracic Oncology Laboratory, Harrison Department of Surgical Research, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA

Address reprint requests to Dr Kaiser, General Thoracic Surgery, Hospital of the University of Pennsylvania, 6 Silverstein Pavilion, Philadelphia, PA 19104
e-mail: kaiser{at}mail.med.upenn.edu

Presented at the Thirty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 25–27, 1999.

Background. Herpes simplex virus (HSV)-1716, a replication-restricted herpes simplex virus type 1, has shown efficacy as an oncolytic treatment for central nervous system tumors, breast cancer, ovarian cancer, and malignant mesothelioma. We evaluated the efficacy of HSV-1716 in a murine lung cancer model, Lewis lung carcinoma.

Methods. Lewis lung carcinoma cells were infected with HSV-1716 and implanted in the flanks of mice at varying ratios of infected to uninfected cells. Tumor burden was assessed by measurement of the weight of the tumor nodule. The role of the immune system was examined by performing experiments in both immunocompetent and SCID mice. Tumors were implanted in the opposite flank to evaluate the vaccine effect.

Results. In immunocompetent and SCID animals, ratio of 1:10 (infected-to-uninfected) cells completely prevented tumor formation and ratio of 1:100 suppressed tumor growth. Established tumors at a distant site in the groups receiving HSV-1716 infected cells showed no difference in size versus control, suggesting absence of a vaccine effect.

Conclusions. We conclude that HSV-1716 may provide a oncolytic therapy for lung cancer even in the absence of immune system induction and a "carrier" cell could potentially deliver this vector.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. A. Ali, J. Lynam, C. S. McLean, C. Entwisle, P. Loudon, J. M. Rojas, S. E. B. McArdle, G. Li, S. Mian, and R. C. Rees
Tumor Regression Induced by Intratumor Therapy with a Disabled Infectious Single Cycle (DISC) Herpes Simplex Virus (HSV) Vector, DISC/HSV/Murine Granulocyte-Macrophage Colony-Stimulating Factor, Correlates with Antigen-Specific Adaptive Immunity
J. Immunol., April 1, 2002; 168(7): 3512 - 3519.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 by The Society of Thoracic Surgeons.